Intelligent Mechanisms of Macrophage Apoptosis Subversion by *Mycobacterium*

Abualgasim Elgaili Abdalla 1,2,*, Hasan Ejaz 1,©, Mahjoob Osman Mahjoob 2, Ayman Ali Mohammed Alameen 1,3, Khalid Omer Abdalla Abosalif 1,2, Mohammed Yagoub Mohammed Elamir 1,2 and Mohammed Alsadig Mousa 2

1 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Al Jouf 2014, Saudi Arabia; hetariq@ju.edu.sa (H.E.); aaalameen@ju.edu.sa (A.A.M.A.); koabosalif@ju.edu.sa (K.O.A.A.); myelamir@ju.edu.sa (M.Y.M.E.)
2 Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Omdurman Islamic University, Omdurman 14415, Sudan
3 Department of Chemical Pathology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum 11081, Sudan

* Correspondence: aealseddig@ju.edu.sa; Tel.: +966-539112018

Received: 25 February 2020; Accepted: 15 March 2020; Published: 16 March 2020

Abstract: Macrophages are one of the first innate defense barriers and play an indispensable role in communication between innate and adaptive immune responses, leading to restricted *Mycobacterium tuberculosis* (*Mt*) infection. The macrophages can undergo programmed cell death (apoptosis), which is a crucial step to limit the intracellular growth of bacilli by liberating them into extracellular milieu in the form of apoptotic bodies. These bodies can be taken up by the macrophages for the further degradation of bacilli or by the dendritic cells, thereby leading to the activation of T lymphocytes. However, *Mt* has the ability to interplay with complex signaling networks to subvert macrophage apoptosis. Here, we describe the intelligent strategies of *Mt* inhibition of macrophages apoptosis. This review provides a platform for the future study of unrevealed *Mt* anti-apoptotic mechanisms and the design of therapeutic interventions.

Keywords: Mycobacterium; macrophage; apoptosis; effector; cytokine; microRNA

1. Introduction

Tuberculosis (TB) is a chronic infectious disease caused by *Mycobacterium tuberculosis* (*Mt*), which affects 10 million people globally. It was one of the top 10 infectious diseases in 2017, with an estimated 1.6 million deaths worldwide, which dropped to 1.5 million in 2018 [1]. *Mt* is considered a sinful intercellular pathogen that is capable of surviving and replicating within the hostile microenvironment of macrophages and other cellular niches [2]. Macrophages are at the frontline of the innate defense, encounter the pathogens, and play a critical role in the containment of bacilli infection through triggering inflammation, digestion of bacilli, and inducing adaptive immune responses [3]. However, *Mt* can subvert macrophage responses such as apoptosis in order to establish a persistent lifestyle [4]. Thus, understanding the underlying mechanisms behind *Mt* manipulation of macrophages apoptosis is decisive for treatment interventions and TB vaccines.

Apoptosis is a highly coordinated and regulated process of the programmed cell death form in which dying cell components and *Mt* are enclosed within cytoplasmic membranes and liberated from the cell called apoptotic bodies [5]. The apoptosis of macrophages is a crucial part of the innate host defense against *Mt* through restricting the intracellular growth of bacilli. The *Mt* infected macrophage undergoes apoptosis in order to release the *Mt* into the extracellular milieu, thereby
leading to the activation of dendritic cells and triggering of robust adaptive immune responses [6,7]. Nevertheless, \textit{Mtb} has evolved multiple mechanisms to revoke macrophages apoptosis, which are discussed in the current review.

### 2. Anti-Apoptotic Determinants of Mycobacterium

\textit{Mtb} has a wide variety of effector molecules that actively block macrophage apoptotic pathways. In this context, cell wall-associated glycolipids, such as lipoarabinomannan (LAM) and mannosylated LAM (ManLAM), are important virulence determinants that have been found to modulate macrophages apoptosis [8,9]. ManLAM can thwart \textit{Mtb} mediating B10R macrophage apoptosis by inhibiting calcium influx and its intracellular signaling. Ablation of calcium-signaling leads to the inhibition of caspase-1 activity, alteration of mitochondrial membrane permeability, as well as induced upregulation of anti-apoptotic, namely, B-cell lymphoma 2 (Bcl2) (Table 1) [8]. LAM can also block human leukemia monocyctic cell (THP-1) apoptosis by activating phosphatidylinositol 3-kinase (PI3K), which in turn activates serine/threonine kinase (Akt) that suppresses pro-apoptotic factor Bad (Table 1) [9].

\textit{Mtb} tyrosine phosphatase (PtpA) is a secreted protein that plays a decisive role in the pathogenesis and survival of \textit{Mtb} within macrophages via interplay with multiple host signaling pathways [10]. PtpA knockout \textit{Mtb} strain induces a high level of caspase-3 expression and promotes its activity in THP-1 macrophages when compared with wild \textit{Mtb} strains. PtpA can block caspase-3 activity by dephosphorylation of human glycogen synthase kinase 3 (GSK3) (Table 1) [11]. Similarly, PtpA can attenuate differentiated U937 macrophages apoptosis in response to Bacillus Calmette–Geurin (BCG) strain infections. PtpA can abolish the ubiquitin ligase of the tripartite motif-containing (TRIM) protein activity, which is required for pro-caspase-3 cleavage [12]. Noticeable, another \textit{Mtb} secreted tyrosine phosphatase (MptpB) is a decisive virulence factor that can modulate macrophage responses and enhance \textit{Mtb} intracellular survival. RAW264.7 cells expressing MptpB displayed much less apoptosis than the control cells when infected with BCG strains. Furthermore, interferon-gamma (IFN-\(\gamma\))-stimulated RAW264.7 cells expressing MptpB show a high viability rate and low levels of cleaved caspase-3 in response to BCG infection when compared RAW264.7 cells-harboring empty vector [13]. Taken together, the anti-apoptotic mechanisms of \textit{Mtb} tyrosine phosphatases are dependent on the inhibition of caspase-3 activation (Table 1).

\textit{Mtb} has 11 types of serine/threonine protein kinases (PknA through PknL) that play a significant role with respect to bacterial adaptation in hostile environments, both in vivo and in vitro [14]. Among them, pknE has anti-apoptotic activity and is indispensable for \textit{Mtb} survival inside the macrophage. PknE deleted \textit{Mtb} strains induce higher levels of THP-1 macrophage apoptosis than the wild type strains and can suppress oxidative stress-inducing cellular apoptosis [15,16]. PknE can modulate the expression of multiple apoptotic molecules and reduce the expression of pro-apoptotic factors, including P53, Bax, and TNF-\(\alpha\), while increasing the expression of anti-apoptotic factor Mcl-1 (Table 1). Furthermore, pknE can promote the phosphorylation of Akt [16], which in turn suppresses the pro-apoptotic factor, i.e., Bad protein [9].

\textit{Mtb} NADH-ubiquinone oxidoreductase subunit G (nuoG), a subunit of type-1 NADH dehydrogenase (NADH-1), was demonstrated to suppressed THP-1 and murine bone marrow-derived macrophages (BMDMs) apoptosis and promoted the pathogenesis of bacilli in a mice infection model [17]. NuoG knockout \textit{Mtb} strains were less virulent and lost their ability to abrogate macrophage apoptosis in comparison with control strains. The ability of nuoG deleted \textit{Mtb} strains to provoke macrophage apoptosis was significantly reversed upon treatment with caspase-3 and caspase-8 inhibitors, or through the ablation of TNF-\(\alpha\) signaling. NuoG can suppress NADPH oxidase (NOX2)-inducing of ROS production leading to inhibition of TNF-\(\alpha\) secretion (Table 1) [18]. A recent study demonstrates that the deletion of \textit{Mtb} TNF-\(\alpha\)-suppressing genes results in increased macrophage apoptosis and promotes a cell-mediated immune response [19]. Therefore, targeting nuoG might improve the immune responses and control the intracellular growth of \textit{Mtb}. 

**Mtb** nucleoside diphosphate kinase (Ndk) acts as a small GTPase inhibitor that can deactivate GTPase Rac1 and, subsequently, inhibit NOX2 assembly and ROS production. Ndk has been demonstrated to block murine macrophage apoptosis by abolishing ROS-mediated caspase-3 cleavage (Table 1) [20].

*Mtb* isocitrate lyase (Icl) is crucial for bacilli viability during latent infection [21]. The recombinant *M. smegmatis*-expressing Icl enhances survival within RAW264.7 murine macrophages and inhibits apoptosis in comparison with *M. smegmatis*-harboring empty vector [22]. Nevertheless, the underlying mechanisms by which Icl subverts macrophage apoptosis are yet to be determined.

*Mtb* PE_PGRS family proteins are the most abundant cell wall anchored proteins that are implicated in bacilli adhesion, invasion, and survival within macrophages and dendritic cells [23]. PE_PGRS62, PE_PGRS41, and PE_PGRS18 contribute actively to revoke macrophage apoptosis [24–26]. The ectopic expression of PE_PGRS62 in *M. smegmatis* enhances its survival within THP-1 macrophages and reduces cell apoptosis. It has been observed that PE_PGRS62 can inhibit the endoplasmic reticulum (ER) stress response (Table 1) by downregulating C/EBP homologous protein (CHOP) and the 78-kDa glucose-regulated protein (GRP78/Bip), which are essential pro-apoptotic factors in response to stress conditions [25]. Likewise, *M. smegmatis*-expressing PE_PGRS41 induces much lower THP-1 macrophage apoptosis than the *M. smegmatis* expressing vector. PE_PGRS41 can decrease the cleavage levels of caspase-9 and caspase-3 (Table 1) [24]. PE_PGRS18 also inhibits THP-1 apoptosis. However, the underlying molecular mechanisms are still unknown [26].

*Mtb* secreted proteins encoded by *Rv3654c* and *Rv3655c* genes express within the cytoplasm of *Mtb*-infected macrophages, suggesting that they may have a role in *Mtb* interplays with host cell signaling [27]. These proteins abrogate the extrinsic pathway-mediated U937 cells apoptosis during *Mtb* infection. They interact and cleave the polypyrrimidine tract binding Protein-associated Splicing Factor (PSF) result in the deactivation of caspase-8 (Table 1) [27]. Similarly, *Rv3033* is a secreted protein that is crucial for *Mtb* viability within macrophages [28]. *Rv3033* has potent anti-apoptotic activity by suppressing the intrinsic apoptotic pathway. *M. smegmatis* expressing *Rv3033* inhibits murine BMDM apoptosis compared with control strains. *Rv3033* can actively block the translocation of pro-apoptotic Bax protein into mitochondria and cytochrome c into cytoplasm, thereby leading to suppress the caspase-9 activation (Table 1) [29]. Likewise, *Rv3365c* is another hypothetical protein that is an important *Mtb* anti-apoptotic effector. The deletion of *Rv3365c* significantly reduces the ability of *Mtb* to suppress U937 cells apoptosis in comparison with wild type strains. *Rv3365c* can revoke cellular apoptosis by interacting and inhibiting host cell membrane-bound serine protease cathepsin G and its downstream activation of caspase-1 (Table 1) [30].

*Mtb* enhanced intracellular survival (Eis) protein is an important modulator of macrophage apoptosis, autophagy, and inflammatory cytokines production. In the context of apoptosis, Eis knockout *Mtb* strain significantly increases the murine BMDM when compared with wild type or complemented strains. Eis can repress JNK signaling leading to inhibition of ROS production (Table 1) [31].

*Mtb* stress response proteins play a significant role in bacterial resistance to the harsh milieu in both *in vitro* and in *vivo* [32,33]. *Mtb* SigH is a stress response regulon that controls the expression of multiple *Mtb* genes in response to oxidative and heat-stressors, as well as to host microenvironments [34,35]. Lower apoptosis of primary rhesus macaque bone marrow-derived macrophage (Rh-BMDM) was observed upon infection with SigH knockdown *Mtb* strains compared with wild *Mtb* strains [33]. SigH regulon can abolish cellular apoptosis through boosting prostaglandin synthetase 2 (PTGS2) expression, which in turn inhibits the P53-dependent apoptotic pathway (Table 1) [33].

*Mtb* Cpn60.2 (GroEL2) is a member of heat shock proteins found in the secreted form within the cytosol of macrophage [32]. Cpn60.2 can revoke THP-1 macrophage apoptosis through interacting with, and enhancing the stability of human mitochondrial Hsp70, which is (Table 1) an important anti-apoptotic factor [32] also known as mortalin [36].
Mtb acpM is a meromycolate extension acyl carrier protein involved in cell wall mycolic acid biosynthesis and a crucial drug target to eradicate multi-drugs-resistant Mtb strains (MDR) [37]. *M. smegmatis* expressing-acpM (Msm-acpM) can enhance the viability of BMDM in comparison with cells infected with *M. smegmatis*, harboring an empty vector. AcpM reduces ROS production by suppressing c-Jun N-terminal Kinase (JNK) signaling (Table 1) [38].

*Mtb* LpqT is a cell wall anchored lipoprotein that modulates macrophage responses by engaging with Toll-Like Receptor-2 (TLR-2) [39]. LpqT deleted *M. smegmatis* strains significantly induce higher levels of RAW264.7 macrophage apoptosis compared with control strains. LpqT could decrease the cleaved levels of caspase-3 by blocking the TLR-2 signaling pathway (Table 1) [39]. However, the previous study demonstrated that LpqT could increase the apoptosis of THP-1 macrophage and monocyte-derived macrophages (MDM) via agonist TLR-2 signaling [40]. Therefore, the exact role of *Mtb* LpqT in the regulation of macrophage apoptosis in the context of its interaction with TLR-2 remains controversial. It has been demonstrated that lipoprotein MPT83 can induce protective immunity against *Mtb* infection via promoting macrophage apoptosis [41].

EspR is an *Mtb* specific protein and a key regulatory protein of the ESX-1 secretion system and many other genes that are involved in *Mtb* pathogenesis [42]. Enforced expression of EspR in RAW264.7 macrophage leading to suppressed BCG mediating apoptosis. EspR can significantly decrease the cleavage of both caspase-3 and caspase-8 (Table 1) when compared with RAW264.7 harboring empty-vector. The mechanisms underlying caspase inhibition was due to EspR interfering with TLRs signaling by directly interacting with myeloid differentiated protein-88 (MyD88) [43].

### Table 1. Anti-apoptotic effectors of *Mycobacterium*.

| Effector | Cell Model | Mechanisms | Outcome | References |
|----------|------------|------------|---------|------------|
| ManLAM   | B10R       | Blocks Ca^{2+} influx to the cells. | Inhibition of caspase-1 cleavage, alter mitochondrial membrane permeability and upregulate Bcl-2 | Rojas et al., 2000 |
| LAM      | THP-1      | Activation of PI3K signaling | Suppression of Bad | Maiti et al., 2001 |
| PtpA     | THP-1      | Dephosphorylation of GSK3 | Inhibition of caspase-3 cleavage | Poirier et al., 2014 |
|          | U937       | Suppress ubiquitin ligase activity of the TRIM protein | Inhibition of caspase-3 cleavage | Wang et al., 2016 |
| MptpA    | RAW264.7   | Reduction of PS3 levels | Inhibition of caspase-3 cleavage | Fan et al., 2018 |
| PknE     | THP-1      | Phosphorylation of Akt | Inhibition of Bad | Kumar and Narayanan et al., 2012 |
|          |            | Inhibit the expression of pro-apoptotic factors, including PS3, TNF-α and Bax | Inhibition of caspase-3 activation | |
|          |            | Promote the anti-apoptotic factor McI-1 expression | Block Bax mitochondrial translocation | |
| NuoG     | THP-1 and BMDM | Blocks of NADPH oxidase mediating ROS production | Inhibition of TNF-α production | Miller et al., 2010 |
| Ndk      | RAW264.7   | Inhibit NOX2 assembly and ROS production | Inhibition of caspase-3 activation | Sun et al., 2013 |
| Icl      | RAW264.7   | Unknown | Unknown | Li et al., 2008 |
| PE_PGRS62| THP-1      | Suppression of pro-apoptotic stress-response genes expressions such as CHOP and GRP78/Bip | Inhibit endoplasmic reticulum (ER) stress response | Long et al., 2019 |
| PE_PGRS41| THP-1      | Uncertain | Reduction the cleavage level of caspase 3 and 9 | Deng et al., 2017 |
| PE_PGRS18| THP-1      | Unknown | Unknown | Yang et al., 2017 |
| Effector | Cell Model | Mechanisms | Outcome | References |
|----------|------------|------------|---------|------------|
| Rv3654c Rv3655c | U937 | Degrade the polypyrimidine tract binding PSF | Suppression of caspase-8 activation | Danelishvili et al., 2010 |
| Rv3033 | RAW264.7 and murine BMDM | Abolish translocation of Bax into mitochondria and cytochrome c into cytoplasm | Suppression of caspase-9 activation | Zhang et al., 2018 |
| Rv3365c | U937 | Inhibit serine cathepsin G | Suppression of caspase-1 | Danelishvili et al., 2012 |
| Eis | Murine BMDM | Block the JNK signaling | Inhibition of ROS production | Shin et al., 2010 |
| SigH | Rh-BMDM | Promote prostaglandin synthetase-2 expression | Inhibition P53 dependent pathway | Dutta et al., 2012 |
| AcpM | Murine BMDM | Suppress JNK signaling | Reduction of ROS production | Paik et al., 2019 |
| LpqT | RAW264.7 | Antagonized TLR-2 signaling | Inhibition of caspase-3 cleavage | Li et al., 2018 |
| EspR | RAW264.7 | Block TLR signaling | Inhibition of caspase-8 and 3 cleavage | Jin et al., 2019 |

PI3K, phosphatidylinositol 3-kinase; GSK3, glycogen synthetase-3; TRIM, tripartite motif; CHOP, C/EBP homologous protein; GRP78/Bip, 78-kDa glucose-regulated protein; PSF, Protein-associated Splicing Factor; TLR, Toll-Like Receptor; JNK, c-Jun N-terminal Kinase; BMDM, bone marrow-derived macrophages; Rh, Rhesus.

3. *Mycobacterium* Thwarts Macrophage Apoptosis by Inducing Anti-Apoptotic Cytokines

Cytokines are inducible, soluble immune mediators responsible for orchestrating various and complex immunological processes, including immune cells crosstalk and apoptosis [44]. *Mtb* can differentially induce cytokines secretion to manipulate macrophage apoptosis. An earlier study showed that *Mycobacterium* could inhibit macrophage apoptosis by robust inducing interleukin-10 (IL-10) production, leading to the increased expression of Bcl2 and decreasing pro-apoptotic factors such as cleaved caspase-1, P53, nitric oxide (NO), and TNF-α production (Figure 1) [45]. Transgenic mice expressing human IL-10 in antigen-presenting cells (APCs) infected with *M. avium* displayed lower levels of macrophage apoptosis, which was accompanied by decreased TNF-α and NO production [46]. IL-10 also inhibits *Mtb* inducing alveolar macrophages (AM) apoptosis by abolishing TNF-α production. In this regard, IL-10 can increase the levels of B-cell lymphoma 3 protein (Bcl-3), which in turn antagonizes TNF-α production via deactivating NF-kappaB nuclear signaling [47].

IL-17A, a cytokine secreted in high amount by T helper-17 (Th17) in response to *Mtb* infection and actively contributes to TB pathogenesis [48]. It has been shown that the exogenous addition of IL-17A can significantly enhance BCG strains and *Mtb* viability within murine BMDM when compared with bacterial intracellular growth in the absence of IL-17A. This cytokine can blockade BMDM apoptosis upon BCG infection by suppression of intrinsic apoptotic pathway through interfering with nuclear translocation of P53, thereby leading to the upregulation of Bcl2 expression and downregulation of Bax expression, as well as abolishing cytochrome c released and caspase-3 activation (Figure 1) [49].

Epstein–Barr virus-induced gene 3 (EBI3), is a subunit of anti-inflammatory cytokines, namely IL-27 and IL-35. It was found that EBI3 is produced in a significant amount in CD14+ macrophages isolated from TB patients compared to cells from healthy donors. Furthermore, it has been demonstrated that EBI3 production and accumulation were markedly increased upon the challenge of murine peritoneal macrophages with *Mtb*, suggesting that it may contribute to the immunoevasion of macrophage responses. *Mtb* and BCG strains shown to induce significant apoptosis of murine EBI3 deleted macrophages in comparison with the deaths of wild type cells. EBI3 abrogates the extrinsic apoptotic pathway via suppression of the cleavage of caspase-3 and caspase-8 (Figure 1) [50]. Taken together, *Mtb* can stimulate IL-10, IL-17A, and EBI3 secretion to frustrate macrophage apoptosis. Thus,
complementary to antibodies blocking the action of these cytokines, anti-tuberculous drugs can hasten the eradication of bacilli and shortage of treatment regimens.

**Figure 1.** Mycobacterium evades macrophage apoptosis by induction of anti-apoptotic cytokines and miRNAs expression. Three cytokines, namely, IL-10, IL-17A, and EBI3, were demonstrated to play an anti-apoptotic role during *Mtb* infection. IL-10 can mediate the expression of anti-apoptotic Bcl2 and Bcl3 protein and suppresses the production of pro-apoptotic factors, including TNF-α, nitric oxide (NO), and P53. IL-17A signaling leads to suppression of P53 mediated Bax mitochondrial translocation. EBI3 can directly inhibit caspase-8 and caspase-3 activation. Nine anti-apoptotic miRs were found selectively regulated by *Mtb*. Has-let-7b-5p can target Fas leading to inhibition of downstream activation of caspase-3. Let-7a and miR-29a are targeting caspase-3 and caspase-7, respectively. MiR-155 can abolish expression of SH2 domain-containing inositol 5-phosphatase 1 (SHIP1), leading to activation of phosphatidylinositol 3-kinase (PI3K) signaling-mediated inhibition of pro-apoptotic factors including Bad, FOXO-1, and 3. In addition, miR-155 can directly targeting and suppressing the expression of FOXO-3. MiR-582-5p can target the mRNA of FOXO-1 and block its expression. MiR-20a-5p can abrogate the activation of pro-apoptotic factor Bim by targeting the JNK-2 signaling pathway. However, miR-20b-5p can enhance the expression of anti-apoptotic factor Mcl-1, which can mediate block Bax mitochondrial translocation. The role of miR-21 in regulating anti-apoptotic Bcl-2 remains controversial.

### 4. *Mtb* can Suppress Apoptosis by Regulating microRNAs Expression

MicroRNAs (miRs) are small noncoding RNAs that play an indispensable role in posttranscriptional regulation of genes expression that involved in various cellular biochemical pathways, including immune signaling pathways in response to pathogenic infections such as *Mtb* [51].

*Mtb* can selectively regulate miRs expression to defeat macrophages apoptosis in order to enhance its intracellular viability and growth. Consistently, miR-582-5p has been significantly more upregulated in monocytes obtained from active TB patients than the cells from healthy controls. The transfection of THP-1 monocytic cells with miR-582-5p mimics leads to the blocking of apoptosis when compared cells transfected with the negative control. MiR-582-5p can inhibit monocytes apoptosis by directly targeting forkhead box O1 (FOXO1) mRNA and suppressing its translation (Figure 1) [52].

MiR-155 expression significantly upregulated in the peripheral blood monocytes (PBMCs) obtained from patients with active TB disease than the cells from healthy control [33]. The apoptosis of CD4+
monocytes was significantly decreased in active TB patients compared with healthy control, suggesting that miR-155 may abolish cellular apoptosis. The ectopic expression of miR-155 in THP-1 macrophages leading to abrogate BCG-inducing apoptosis via downregulating FOXO3 expression (Figure 1) [53]. Furthermore, Mtb infected miR-155 knockdown murine macrophages exhibited a higher level of apoptosis when compared with wild type macrophages infected with Mtb [54]. MiR-155 can target the mRNA of SH2 domain-containing inositol 5-phosphatase 1(SHIP1), which was confirmed by increased protein levels in miR-155 deleted macrophages. Increased levels of SHIP1 can result in reduced phosphorylation of Akt, thereby leading to the enhanced activation of Bad, FOXO-1, 3, and caspase-3 (Figure 1) [54].

MiR-223 is expressed significantly more in peripheral macrophages harvested from active TB patients compared with cells from healthy controls and upregulated during the in vitro Mtb infection of human macrophages. The forced expression miR-223 in human macrophages significantly reduced the rate of apoptosis in comparison with macrophages transfected with control miR-223 mimics. Mechanistically, miR-223 blocks macrophage apoptosis by targeting FOXO3 and markedly reducing its protein expression (Figure 1) [55].

Let-7e and miR-29a are highly expressed in human monocyte-derived macrophages in response to M. avium infection. They block macrophages apoptosis by repressing the expression of caspase-3 and 7, which are direct targets for let-7e and miR-29a, respectively (Figure 1) [56].

MiR-21 expression was upregulated by NF-κB signaling in RAW264.7 murine macrophage triggered by Mtb mpt68 protein. It has been demonstrated that miR-21 could inhibit murine macrophage apoptosis by positively regulating anti-apoptotic Bcl-2 expression (Figure 1) [57]. However, recent studies have demonstrated that miR-21 enhances macrophages apoptosis in response to mycobacterium infection by negatively regulating the expression of Bcl-2 [58,59]. Therefore, the role of miR-21 in regulating macrophage apoptosis and Bcl-2 expression remains ambiguous.

MiR-20a-5p expression was found to be downregulated in CD14+ monocytes from active pulmonary TB patients, while it is pronouncedly upregulated by successful anti-TB treatment. The downregulation of miR-20a-5p expression also observed during the Mtb infection of THP-1 human macrophages. Blockade of miR-20a-5p expression can accelerate THP-1 macrophage apoptosis and promote mycobacterium survival. MiR-20a-5p ectopically expressed in THP-1 cells led to the decreased expression of pro-apoptotic gene Bim through targeting and abolishing the expression of JNK2 signaling (Figure 1) [60]. Recently, the downregulation of miR-20b-5p expression has been reported upon the Mtb infection of RAW264.7 macrophages. The overexpression of miR-20b-5p can promote bacilli survival and cell apoptosis [61]. In this regard, miR-20b-5p can increase macrophage apoptosis by targeting and suppressing the expression of the anti-apoptotic Mcl-1 gene (Figure 1) [61], which is a member of the Bcl-2 protein family.

Hsa-let-7b-5p was significantly upregulated in Mtb infected THP-1 macrophages, leading to the subversion of apoptosis. Mechanistically, hsa-let-7b-5p negatively regulates the expression of Fas by directly targeting its mRNA, which can lead to blocking pathways of caspase-3 activation (Figure 1) [62].

5. Conclusions

Macrophages are the first line of innate defense against Mtb infection, and the subversion of macrophage apoptosis is considered a hallmark of Mtb pathogenesis. Mtb is a mystery pathogen that utilizes multiple strategies to abolish apoptotic signaling pathways in order to establish persistent infection. The impairment of macrophage apoptosis leads to the enhanced intracellular survival of bacilli and compromises the cell-mediated immune response. Mtb has a broad spectrum of anti-apoptotic effector molecules that direct targeting cellular pro-apoptotic factors or block the signaling that regulates their expression. Some Mtb anti-apoptotic effectors, including PE_PGRS18 and IcI, impaired macrophage apoptosis by unrecognized mechanisms. Moreover, the role of Mycobacterium lipoprotein (LpqT) in modulating macrophage apoptosis needed to be clarified. Future studies are
needed to identify unrevealed mechanisms of \textit{Mtb} anti-apoptotic effectors and to develop methods able to hamper \textit{Mtb} effectors’ capability to abrogate macrophage apoptosis.

\textit{Mtb} can also manipulate macrophage apoptosis by selectively regulating cytokines and miRs expression. It is also important to understand how \textit{Mtb} selectively regulates anti-apoptotic cytokines and miRs expression. The mechanisms by which cytokines and miRs enhance the viability of macrophages are dependent on the aberrant activity of key pro-apoptotic regulators, including P53, TNF-\textgreek{a}, Fas, FOXO, and Bad. They promote the activity of anti-apoptotic regulators such as SHIP, Bcl-2, and Mcl-1. Taken together, these insights into the intelligent subversion mechanisms of macrophage apoptosis by \textit{Mtb} elucidate promising and novel therapeutic targets to eliminate the intracellular survival of bacilli and promote an adaptive immune response.

\textbf{Author Contributions:} A.E.A. conceived the idea and drafted the manuscript. M.O.M., A.A.M.A., K.O.A.A., M.Y.M.E., and M.A.M. reviewed the literature and helped in the drafting and analysis of the manuscript. H.E. contributed in drafting and critical revision of the manuscript. All authors have read and agree to the published version of the manuscript.

\textbf{Funding:} This research received no external funding.

\textbf{Conflicts of Interest:} The authors declare no conflict of interest.

\section*{References}
1. World Health Organization. \textit{Global Tuberculosis Report 2019}; World Health Organization: Geneva, Switzerland, 2019; Available online: https://www.who.int/tb/publications/global_report/en/ (accessed on 17 October 2019).
2. Marakalala, M.J.; Martinez, F.O.; Plüddemann, A.; Gordon, S. Macrophage heterogeneity in the immunopathogenesis of tuberculosis. Front. Microbiol. \textbf{2018}, \textit{9}, 1028. [CrossRef] [PubMed]
3. Ferraris, D.; Miggiano, R.; Rossi, F.; Rizzi, M. \textit{Mycobacterium tuberculosis} molecular determinants of infection, survival strategies, and vulnerable targets. \textit{Pathogens} \textbf{2018}, \textit{7}, 17. [CrossRef] [PubMed]
4. Hmama, Z.; Peña-Díaz, S.; Joseph, S.; Av-Gay, Y. Immunoevasion and immunosuppression of the macrophage by \textit{Mycobacterium tuberculosis}. \textit{Immunol. Rev.} \textbf{2015}, \textit{264}, 220–232. [CrossRef] [PubMed]
5. Divangahi, M.; Behar, S.M.; Remold, H. Dying to live: How the death modality of the infected macrophage affects immunity to tuberculosis. \textit{Adv. Exp. Med. Biol.} \textbf{2013}, \textit{783}, 103–120. [CrossRef] [PubMed]
6. Weiss, G.; Schaible, U.E. Macrophage defense mechanisms against intracellular bacteria. \textit{Immunol. Rev.} \textbf{2015}, \textit{264}, 182–203. [CrossRef] [PubMed]
7. Kelly, D.M.; ten Bokum, A.M.; O'Leary, S.M.; O'Sullivan, M.P.; Keane, J. Bystander macrophage apoptosis after \textit{Mycobacterium tuberculosis} H37Ra infection. \textit{Infect. Immun.} \textbf{2008}, \textit{76}, 351–360. [CrossRef] [PubMed]
8. Rojas, M.; García, L.F.; Nigou, J.; Puzo, G.; Olivier, M. Mannosylated lipoarabinomannan antagonizes \textit{Mycobacterium tuberculosis}-induced macrophage apoptosis by altering Ca+2-dependent cell signaling. \textit{J. Infect. Dis.} \textbf{2000}, \textit{182}, 240–251. [CrossRef]
9. Maiti, D.; Bhattacharyya, A.; Basu, J. Lipoarabinomannan from \textit{Mycobacterium tuberculosis} promotes macrophage survival by phosphorylating bad through a phosphatidylinositol 3-kinase/Akt pathway. \textit{J. Biol. Chem.} \textbf{2001}, \textit{276}, 329–333. [CrossRef]
10. Wong, D.; Chao, J.D.; Av-Gay, Y. \textit{Mycobacterium tuberculosis}-secreted phosphatases: From pathogenesis to targets for TB drug development. \textit{Trends Microbiol.} \textbf{2013}, \textit{21}, 100–109. [CrossRef]
11. Poirier, V.; Bach, H.; Av-Gay, Y. \textit{Mycobacterium tuberculosis} promotes anti-apoptotic activity of the macrophage by PtpA protein-dependent dephosphorylation of host GSK3\textgreek{a}. \textit{J. Biol. Chem.} \textbf{2014}, \textit{289}, 29376–29385. [CrossRef]
12. Wang, J.; Teng, J.L.; Zhao, D. The ubiquitin ligase TRIM27 functions as a host restriction factor antagonized by \textit{Mycobacterium tuberculosis} PtpA during mycobacterial infection. \textit{Sci. Rep.} \textbf{2016}, \textit{6}, 34827. [CrossRef] [PubMed]
13. Fan, L.; Wu, X.; Jin, C.; Li, F.; Xiong, S.; Dong, Y. MptpB promotes \textit{Mycobacteria} survival by inhibiting the expression of inflammatory mediators and cell apoptosis in macrophages. \textit{Front. Cell Infect. Microbiol.} \textbf{2018}, \textit{8}, 171. [CrossRef] [PubMed]
14. Prisic, S.; Husson, R.N. \textit{Mycobacterium tuberculosis} serine/threonine protein kinases. \textit{Microbiol. Spectr.} \textbf{2014}, \textit{2}, 1–42. [CrossRef]
15. Jayakumar, D.; Jacobs, W.R.; Narayanan, S. Protein kinase E of *Mycobacterium tuberculosis* has a role in the nitric oxide stress response and apoptosis in a human macrophage model of infection. *Cell Microbiol.* 2008, 10, 365–374. [CrossRef]

16. Kumar, D.; Narayanan, S. pknE, a serine/threonine kinase of *Mycobacterium tuberculosis* modulates multiple apoptotic paradigms. *Infect. Genet. Evol.* 2012, 12, 737–747. [CrossRef]

17. Velmurugan, K.; Chen, B.; Miller, J.L. *Mycobacterium tuberculosis* nuoG is a virulence gene that inhibits apoptosis of infected host cells. *PLoS Pathog.* 2007, 3, e110. [CrossRef]

18. Miller, J.L.; Velmurugan, K.; Cowan, M.J.; Briken, V. The type I NADH dehydrogenase of *Mycobacterium tuberculosis* counters phagosomal NOX2 activity to inhibit TNF-α-mediated host cell apoptosis. *PLoS Pathog.* 2010, 6, e1000864. [CrossRef]

19. Olsen, A.; Chen, Y.; Ji, Q.; Zhu, G.; De Silva, A.D.; Vilchis, T.; Li, W.; Xu, J.; Larsen, M.; et al. Targeting *Mycobacterium tuberculosis* tumor necrosis factor alpha-downregulating genes for the development of antituberculous vaccines. *MBio* 2016, 7, e01023-15. [CrossRef]

20. Sun, J.; Singh, V.; Lau, A.; Stokes, R.W.; Obregon-Henao, A.; Orme, I.M.; Wong, D.; Av-Gay, Y.; Hmama, Z. *Mycobacterium tuberculosis* nucleoside diphosphate kinase inactivates small GTPases leading to evasion of innate immunity. *PLoS Pathog.* 2013, 9, e1003499. [CrossRef]

21. Bhushal, R.P.; Bashiri, G.; Kwai, B.X.; Sperry, J.; Leung, I.K. Targeting isocitrate lyase for the treatment of latent tuberculosis. *Drug Discov. Today* 2017, 22, 1008–1016. [CrossRef]

22. Li, J.M.; Na, L.; Zhu, D.Y.; Wan, L.G.; He, Y.L.; Chun, Y. Isocitrate lyase from *Mycobacterium tuberculosis* promotes survival of *Mycobacterium smegmatis* within macrophage by suppressing cell apoptosis. *Chin. Med. J.* 2008, 121, 1114–1119. [CrossRef] [PubMed]

23. Meena, L.S. An overview to understand the role of PE_PGRS family proteins in *Mycobacterium tuberculosis* H37Rv and their potential as new drug targets. *Biotechnol. Appl. Biochem.* 2015, 62, 145–153. [CrossRef] [PubMed]

24. Deng, W.; Long, Q.; Zeng, J.; Li, P.; Yang, W.; Chen, X.; Xie, J. *Mycobacterium tuberculosis* PE_PGRS41 enhances the intracellular survival of *M. smegmatis* within macrophages via blocking innate immunity and inhibition of host defense. *Sci. Rep.* 2017, 7, 46716. [CrossRef] [PubMed]

25. Long, Q.; Xiang, X.; Yin, Q.; Li, S.; Yang, W.; Sun, H.; Xie, J.; Deng, W. *PE_PGRS62* promotes the survival of *Mycobacterium smegmatis* within macrophages via disrupting ER stress-mediated apoptosis. *J. Cell. Physiol.* 2019, 234, 19774–19784. [CrossRef] [PubMed]

26. Yang, W.; Deng, W.; Zeng, J.; Ren, S.; Ali, M.K.; Gu, Y.; Li, Y.; Xie, J. *Mycobacterium tuberculosis* PE_PGRS18 enhances the intracellular survival of *M. smegmatis* via altering host macrophage cytokine profiling and attenuating the cell apoptosis. *Apoptosis* 2017, 22, 502–509. [CrossRef]

27. Danelishvili, L.; Yamazaki, Y.; Selker, J.; Bermudez, L.E. Secreted *Mycobacterium tuberculosis* Rv3654c and Rv3655c proteins participate in the suppression of macrophage apoptosis. *PLoS ONE* 2010, 5, e10474. [CrossRef]

28. Rengarajan, J.; Bloom, B.R.; Rubin, E.J. Genome-wide requirements for *Mycobacterium tuberculosis* adaptation and survival in macrophages. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8327–8332. [CrossRef]

29. Zhang, W.; Lu, Q.; Dong, Y.; Yue, Y.; Xiong, S. Rv3033, as an Emerging Anti-apoptosis Factor, Facilitates Mycobacteria Survival via Inhibiting Macrophage Intrinsic Apoptosis. *Front. Immunol.* 2018, 9, 2136. [CrossRef]

30. Danelishvili, L.; Everman, J.; McNamara, M.; Bermudez, L. Inhibition of the plasma-membrane-associated serine protease cathepsin G by *Mycobacterium tuberculosis* Rv3364c suppresses caspase-1 and pyroptosis in macrophages. *Front. Microbiol.* 2012, 2, 281. [CrossRef]

31. Shin, D.M.; Jeon, B.Y.; Lee, H.M.; Jin, H.S.; Yuk, J.M.; Song, C.H.; Lee, S.H.; Lee, Z.W.; Cho, S.N.; Kim, J.M.; et al. *Mycobacterium tuberculosis* eis regulates autophagy, inflammation, and cell death through redox-dependent signaling. *PLoS Pathog.* 2010, 6, e1001230. [CrossRef]

32. Joseph, S.; Yuen, A.; Singh, V.; Hmama, Z. *Mycobacterium tuberculosis* Cpn60. 2 (GroEL2) blocks macrophage apoptosis via interaction with mitochondrial mortalain. *Biol. Open* 2017, 6, 481–488. [CrossRef] [PubMed]

33. Dutta, N.K.; Mehra, S.; Martinez, A.N.; Alvarez, X.; Renner, N.A.; Morici, L.A.; Pahar, B.; Maclean, A.G.; Lackner, A.A.; Kaushal, D. The stress-response factor SigH modulates the interaction between *Mycobacterium tuberculosis* and host phagocytes. *PLoS ONE* 2012, 7, e28938. [CrossRef]
34. Raman, S.; Song, T.; Puyang, X.; Bardarov, S.; Jacobs, W.R.; Husson, R.N. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in *Mycobacterium tuberculosis*. *J. Bacteriol.* 2001, 183, 6119–6125. [CrossRef] [PubMed]

35. Mehra, S.; Golden, N.A.; Stuckey, K.; Didier, P.J.; Doyle, L.A.; Russell-Lodrigue, K.E.; Sugimoto, C.; Hasegawa, A.; Sivasubramani, S.K.; Roy, C.J.; et al. The *Mycobacterium tuberculosis* stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. *J. Infect. Dis.* 2012, 205, 1203–1213. [CrossRef] [PubMed]

36. Londono, C.; Osorio, C.; Gama, V.; Alzate, O. Mortalina, apoptosis, and neurodegeneration. *Biomolecules* 2012, 2, 143–164. [CrossRef]

37. Kaur, D.; Mathew, S.; Nair, C.; Begum, A.; Jainanarayan, A.K.; Sharma, M.; Brahmacchari, S.K. Structure based drug discovery for designing targets for non-toxic metabolic targets in multi drug resistant *Mycobacterium tuberculosis*. *J. Transl. Med.* 2017, 15, 261. [CrossRef]

38. Paik, S.; Choi, S.; Lee, K.I.; Back, Y.W.; Son, Y.J.; Jo, E.K.; Kim, H.J. *Mycobacterium tuberculosis* acyl carrier protein inhibits macrophage apoptotic death by modulating the reactive oxygen species/c-Jun N-terminal kinase pathway. *Microbes Infect.* 2019, 21, 40–49. [CrossRef]

39. Li, F.; Feng, L.; Jin, C.; Wu, X.; Fan, L.; Xiong, S.; Dong, Y. LpqT improves mycobacteria survival in macrophages by inhibiting TLR2 mediated inflammatory cytokine expression and cell apoptosis. *Tuberculosis* 2018, 111, 57–66. [CrossRef]

40. Su, H.; Zhu, S.; Zhu, L.; Huang, W.; Wang, H.; Zhang, Z.; Xu, Y. Recombinant lipoprotein Rv1016c derived from *Mycobacterium tuberculosis* is a TLR-2 ligand that induces macrophages apoptosis and inhibits MHC II antigen processing. *Front. Cell. Infect. Microbiol.* 2016, 6, 147. [CrossRef]

41. Blasco, B.; Chen, J.M.; Hartkoorn, R.; Sala, C.; Uplekar, S.; Rougemont, J.; Pojer, F.; Cole, S.T. Virulence regulator EspR of *Mycobacterium tuberculosis* is a nucleoid-associated protein. *PLoS Pathog.* 2012, 8, e1002621. [CrossRef]

42. Wang, L.; Zuo, M.; Chen, H.; Liu, S.; Wu, X.; Cui, Z.; Yang, H.; Liu, H.; Ge, B. *Mycobacterium tuberculosis* lipoprotein MPT83 induces apoptosis of infected macrophages by activating the TLR2/p38/COX-2 signaling pathway. *J. Immunol.* 2017, 198, 4772–4780. [CrossRef] [PubMed]

43. Jin, C.; Wu, X.; Dong, C.; Li, F.; Fan, L.; Xiong, S.; Dong, Y. EspR promotes mycobacteria survival in macrophages by inhibiting MyD88 mediated inflammation and apoptosis. *Tuberculosis* 2019, 116, 22–31. [CrossRef] [PubMed]

44. Etna, M.P.; Giacomini, E.; Severa, M.; Coccia, E.M. Pro-and anti-inflammatory cytokines in tuberculosis: A two-edged sword in TB pathogenesis. *Semin. Immunol.* 2014, 26, 543–551. [CrossRef] [PubMed]

45. Balcewicz-Sablinska, M.K.; Gan, H.; Remold, H. Interleukin 10 produced by macrophages inoculated with *Mycobacterium avium* attenuates mycobacteria-induced apoptosis by reduction of TNF-α activity. *J. Infect Dis.* 1999, 180, 1230–1237. [CrossRef] [PubMed]

46. Feng, C.G.; Kullberg, M.C.; Jankovic, D.; Cheever, A.W.; Caspar, P.; Coffman, R.L.; Sher, A. Transgenic mice expressing human interleukin-10 in the antigen-presenting cell compartment show increased susceptibility to infection with *Mycobacterium avium* associated with decreased macrophage effector function and apoptosis. *Infect. Immun.* 2002, 70, 6672–6679. [CrossRef] [PubMed]

47. Patel, N.R.; Swan, K.; Li, X.; Tachado, S.D.; Koziel, H. Impaired *M. tuberculosis*—Mediated apoptosis in alveolar macrophages from HIV+ persons: Potential role of IL-10 and BCL-3. *J. Leukoc. Biol.* 2009, 86, 53–60. [CrossRef]

48. Pollara, G.; Turner, C.T.; Tomlinson, G.S.; Bell, L.C.; Khan, A.; Peralta, L.F.; Ricciardolo, F.L. Exaggerated in vivo IL-17 responses discriminate recall responses in active TB. *bioRxiv* 2019. bioRxiv: 516690.

49. Cruz, A.; Ludovico, P.; Torrado, E.; Gama, J.B.; Sousa, J.; Gaifem, J.; Appelberg, R.; Rodrigues, F.; Cooper, A.M.; Pedrosa, J.; et al. IL-17A promotes intracellular growth of *Mycobacterium* by inhibiting apoptosis of infected macrophages. *Front. Immunol.* 2015, 6, 498. [CrossRef]

50. Deng, J.H.; Chen, H.Y.; Huang, C.; Yan, J.M.; Yin, Z.; Zhang, X.L.; Pan, Q. Accumulation of EBI3 induced by virulent *Mycobacterium tuberculosis* inhibits apoptosis in murine macrophages. *Pathog. Dis.* 2019, 77, ftz007. [CrossRef]

51. Zhou, X.; Li, X.; Wu, M. miRNAs reshape immunity and inflammatory responses in bacterial infection. *Signal Transduct. Target. Ther.* 2018, 3, 14. [CrossRef]
52. Liu, Y.; Jiang, J.; Wang, X.; Zhai, F.; Cheng, X. miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1. *PLoS ONE* 2013, 8, e78381. [CrossRef] [PubMed]

53. Huang, J.; Jiao, J.; Xu, W.; Zhao, H.; Zhang, C.; Shi, Y.; Xiao, Z. MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. *Mol. Med. Rep.* 2015, 12, 7102–7108. [CrossRef] [PubMed]

54. Rothchild, A.C.; Sissons, J.R.; Shafiani, S.; Plaisier, C.; Min, D.; Mai, D.; Gilchrist, M.; Peschon, J.; Larson, R.P.; Berghalter, A.; et al. MiR-155–regulated molecular network orchestrates cell fate in the innate and adaptive immune response to *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* 2016, 113, E6172–E6181. [CrossRef] [PubMed]

55. Xi, X.; Zhang, C.; Han, W.; Zhao, H.; Zhang, H.; Jiao, J. MicroRNA-223 is upregulated in active tuberculosis patients and inhibits apoptosis of macrophages by targeting FOXO3. *Genet. Test. Mol. Biomark.* 2015, 19, 650–656. [CrossRef]

56. Sharbati, J.; Lewin, A.; Kutz-Lohroff, B.; Kamal, E.; Einspanier, R.; Sharbati, S. Integrated microRNA-mRNA-analysis of human monocyte derived macrophages upon *Mycobacterium avium subsp. hominissuis* infection. *PLoS ONE* 2011, 6, e20258. [CrossRef]

57. Wang, Q.; Liu, S.; Tang, Y.; Liu, Q.; Yao, Y. MPT64 protein from *Mycobacterium tuberculosis* inhibits apoptosis of macrophages through NF-kB-miRNA21-Bcl-2 pathway. *PLoS ONE* 2014, 9, e100949. [CrossRef]

58. Xue, X.; Qiu, Y.; Yang, H.L. Immunoregulatory role of MicroRNA-21 in macrophages in response to bacillus calmette-guerin infection involves modulation of the TLR4/MyD88 signaling pathway. *Cell. Physiol. Biochem.* 2017, 42, 91–102. [CrossRef]

59. Zhao, Z.; Hao, J.; Li, X.; Chen, Y.; Qi, X. MiR-21-5p regulates mycobacterial survival and inflammatory responses by targeting Bcl-2 and TLR4 in *Mycobacterium tuberculosis*-infected macrophages. *FEBS Lett.* 2019, 593, 1326–1335. [CrossRef]

60. Zhang, G.; Liu, X.; Wang, W.; Cai, Y.; Li, S.; Chen, Q.; Liao, M.; Zhang, M.; Zeng, G.; Zhou, B.; et al. Down-regulation of miR-20a-5p triggers cell apoptosis to facilitate mycobacterial clearance through targeting [NK2 in human macrophages. *Cell Cycle* 2016, 15, 2527–2538. [CrossRef]

61. Zhang, D.; Yi, Z.; Fu, Y. Downregulation of miR-20b-5p facilitates Mycobacterium tuberculosis survival in RAW 264.7 macrophages via attenuating the cell apoptosis by Mcl-1 upregulation. *J. Cell. Biochem.* 2019, 120, 5889–5896. [CrossRef]

62. Tripathi, A.; Srivastava, V.; Singh, B.N. hsa-let-7b-5p facilitates Mycobacterium tuberculosis survival in THP-1 human macrophages by Fas downregulation. *FEMS Microbiol. Lett.* 2018, 365, fny040. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).